Internal Medicine, Medical Oncology · Baton Rouge, LA
NPI
1245217728
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
7777 Hennessy Blvd Ste 6000
Baton Rouge, LA, 70808
Phone (225) 757-0343
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.8M
113,420 services
Medicare patients, 2024
599
Average age 76
Drug cost, 2024
$8.4M
2,571 prescriptions
Company payments, 2025
$4,088
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Gerald P Miletello was code J0897 (injection, denosumab, 1 mg), 8,760 times for 29 patients. In total Gerald P Miletello billed 113,420 services in 132 codes, and Medicare paid $2.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-10-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 8,760 | 29 | $20.19 | $177K |
| J0185 Injection, aprepitant, 1 mg | Office | 8,320 | 12 | $1.34 | $11K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 4,000 | 33 | $15.44 | $62K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,841 | 38 | $0.09 | $164 |
| 36415 Venipuncture Blood Collection | Office | 1,541 | 512 | $8.61 | $13K |
| 85025 Blood Count | Office | 1,405 | 497 | $7.58 | $11K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,140 | 19 | $0.76 | $863 |
| 99214 Office E&M - Established | Office | 1,129 | 495 | $84.19 | $95K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 584 | 23 | $0.07 | $43.17 |
| 96375 Injection Administration | Office | 500 | 49 | $10.54 | $5,270 |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 285 | 50 | $69.43 | $20K |
| 96413 Chemotherapy Administration | Office | 279 | 53 | $86.47 | $24K |
| 96372 Injection Administration | Office | 146 | 35 | $9.77 | $1,426 |
| 96402 Chemotherapy Administration | Office | 111 | 13 | $23.61 | $2,620 |
| 99233 Hospital E&M - Subsequent | Facility | 100 | 38 | $87.00 | $8,700 |
By year: 2022 $3.9M for 208,820 services; 2023 $4.6M for 216,593 services; 2024 $2.8M for 113,420 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,541 | 512 | $8.61 | $13K |
| 85025 Blood Count | 1,405 | 497 | $7.58 | $11K |
| 81002 Clinical Chemistry | 39 | 11 | $3.41 | $133 |
Medicare prescription drug claims, 2024
In 2024, the drug Gerald P Miletello prescribed most often to Medicare patients was Gabapentin, with 155 prescriptions and refills. In total Gerald P Miletello wrote 2,571 Medicare prescriptions that cost $8.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 155 | 243 | 42 | $723 |
| Revlimid Lenalidomide | 133 | 133 | 16 | $2.0M |
| Letrozole Generic | 120 | 282 | 38 | $2,895 |
| Anastrozole Generic | 113 | 283 | 32 | $2,139 |
| Prednisone Generic | 107 | 119 | 38 | $637 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 80 | 80 | 36 | $1,219 |
| Levothyroxine Sodium Generic | 79 | 111 | 12 | $574 |
| Dexamethasone Generic | 67 | 77 | 19 | $1,161 |
| Ibrance Palbociclib | 53 | 53 | Under 11 | $838K |
| Ondansetron Hcl Generic | 52 | 52 | 32 | $440 |
| Alprazolam Generic | 51 | 59 | 23 | $270 |
| Pantoprazole Sodium Generic | 50 | 64 | 13 | $467 |
| Prochlorperazine Maleate Generic | 48 | 48 | 30 | $433 |
| Cabometyx Cabozantinib S-Malate | 48 | 48 | Under 11 | $1.2M |
| Orgovyx Relugolix | 45 | 45 | Under 11 | $120K |
Brand drugs: - claims; generic drugs: 1,886 claims; opioid claims: 155.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Gerald P Miletello $4,088 ($4,088 in general payments such as food, travel and fees) from 41 companies. The largest payer was Merck Sharp & Dohme LLC with $380.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 14 | $380 |
| AstraZeneca Pharmaceuticals LP AZN | 16 | $330 |
| Novartis Pharmaceuticals Corporation NVS | 14 | $303 |
| E.R. Squibb & Sons, L.L.C. BMY | 11 | $284 |
| Abbvie Inc. ABBV | 7 | $233 |
| Janssen Biotech, Inc. JNJ | 7 | $214 |
| Genentech USA, Inc. ROG.SW | 7 | $170 |
| BeOne Medicines USA, Inc. ONC | 4 | $167 |
| GlaxoSmithKline, LLC. GSK | 9 | $151 |
| Genzyme Corporation SNY | 8 | $150 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.